These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 17008537

  • 1. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
    Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS, Heerema NA, Smith L, Grever MR, Byrd JC.
    Blood; 2007 Jan 15; 109(2):405-11. PubMed ID: 17008537
    [Abstract] [Full Text] [Related]

  • 2. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
    Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS.
    Cancer; 2013 Nov 01; 119(21):3788-96. PubMed ID: 23922059
    [Abstract] [Full Text] [Related]

  • 3. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.
    Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA, Weiss MA.
    J Clin Oncol; 2006 Apr 01; 24(10):1575-81. PubMed ID: 16520464
    [Abstract] [Full Text] [Related]

  • 4. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.
    Kay NE, Wu W, Kabat B, LaPlant B, Lin TS, Byrd JC, Jelinek DF, Grever MR, Zent CS, Call TG, Shanafelt TD.
    Cancer; 2010 May 01; 116(9):2180-7. PubMed ID: 20187101
    [Abstract] [Full Text] [Related]

  • 5. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD.
    Clin Lymphoma Myeloma; 2005 Sep 01; 6(2):131-5. PubMed ID: 16231851
    [Abstract] [Full Text] [Related]

  • 6. A phase I and II study of pentostatin (Nipent) with cyclophosphamide for previously treated patients with chronic lymphocytic leukemia.
    Weiss MA.
    Semin Oncol; 2000 Apr 01; 27(2 Suppl 5):41-3. PubMed ID: 10877051
    [Abstract] [Full Text] [Related]

  • 7. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
    Reynolds C, Di Bella N, Lyons RM, Hyman W, Richards DA, Robbins GJ, Vellek M, Boehm KA, Zhan F, Asmar L.
    Invest New Drugs; 2012 Jun 01; 30(3):1232-40. PubMed ID: 21922186
    [Abstract] [Full Text] [Related]

  • 8. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
    Zent CS, Taylor RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, Call TG, Bowen DA, Conte MJ, Frederick LA, Link BK, Blackwell SE, Veeramani S, Baig NA, Viswanatha DS, Weiner GJ, Witzig TE.
    Am J Hematol; 2014 Jul 01; 89(7):757-65. PubMed ID: 24723493
    [Abstract] [Full Text] [Related]

  • 9. Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).
    Kempin S, Sun Z, Kay NE, Paietta EM, Mazza JJ, Ketterling RP, Frankfurt O, Claxton DF, Saltzman JN, Srkalovic G, Callander NS, Gross G, Tallman MS.
    Acta Haematol; 2019 Jul 01; 142(4):224-232. PubMed ID: 31336367
    [Abstract] [Full Text] [Related]

  • 10. Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia.
    Kay NE, LaPlant BR, Pettinger AM, Call TG, Leis JF, Ding W, Parikh SA, Conte MJ, Bowen DA, Shanafelt TD.
    Expert Rev Hematol; 2018 Apr 01; 11(4):337-349. PubMed ID: 29460654
    [Abstract] [Full Text] [Related]

  • 11. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL, Figgitt DP.
    Drugs; 2003 Apr 01; 63(8):803-43. PubMed ID: 12662126
    [Abstract] [Full Text] [Related]

  • 12. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T, Lech-Maranda E, Robak P.
    Expert Rev Anticancer Ther; 2010 Oct 01; 10(10):1529-43. PubMed ID: 20942624
    [Abstract] [Full Text] [Related]

  • 13. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
    Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR, Blood Cancer Research Partnership of the Leukemia & Lymphoma Society.
    Lancet Haematol; 2019 Aug 01; 6(8):e419-e428. PubMed ID: 31208944
    [Abstract] [Full Text] [Related]

  • 14. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.
    Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM.
    Leuk Res; 2013 Oct 01; 37(10):1195-9. PubMed ID: 23867058
    [Abstract] [Full Text] [Related]

  • 15. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
    Weiss MA, Maslak PG, Jurcic JG, Scheinberg DA, Aliff TB, Lamanna N, Frankel SR, Kossman SE, Horgan D.
    J Clin Oncol; 2003 Apr 01; 21(7):1278-84. PubMed ID: 12663715
    [Abstract] [Full Text] [Related]

  • 16. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
    Lamanna N, Jurcic JG, Noy A, Maslak P, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, Golde DW, Scheinberg DA, Zelenetz AD, Weiss MA.
    J Clin Oncol; 2009 Feb 01; 27(4):491-7. PubMed ID: 19075280
    [Abstract] [Full Text] [Related]

  • 17. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
    Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG.
    Blood; 2011 Aug 25; 118(8):2062-8. PubMed ID: 21750315
    [Abstract] [Full Text] [Related]

  • 18. Pentostatin treatment combinations in chronic lymphocytic leukemia.
    Lamanna N, Kay NE.
    Clin Adv Hematol Oncol; 2009 Jun 25; 7(6):386-92. PubMed ID: 19606074
    [Abstract] [Full Text] [Related]

  • 19. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S.
    Lancet Oncol; 2014 Sep 25; 15(10):1090-9. PubMed ID: 25150798
    [Abstract] [Full Text] [Related]

  • 20. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.
    Kay NE, Strati P, LaPlant BR, Leis JF, Nikcevich D, Call TG, Pettinger AM, Lesnick CE, Hanson CA, Shanafelt TD.
    Oncotarget; 2016 Nov 29; 7(48):78269-78280. PubMed ID: 27861157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.